In this study, we employed a murine epilepsy model treated with the KMO inhibitor Ro 61-8048, a selective inhibitor extensively validated preclinically that specifically binds and inhibits KMO enzymatic activity [25,26,27]. Here, KMO is linked to epilepsy.